Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer

por Ulahannan, Susanna V, Brahmer, Julie R
Publicado 2011

Paired tumor biopsy analysis and safety data from a pilot study evaluating Tremelimumab - a monoclonal antibody against CTLA-4 - in combination with ablative therapy in patients wi...

por Duffy, Austin, Kerkar, Sid P, Kleiner, David E, Ulahannan, Susanna, Kurtoglu, Metin, Rusher, Oxana, Fioravanti, Suzanne, Walker, Melissa, Figg, William D, Compton, Kathryn, Venkatesan, Aradhana, Abi-Jaoudeh, Nadine, Wood, Brad, Greten, Tim F
Publicado 2014

Targeting Doublecortin-Like Kinase 1 (DCLK1)-Regulated SARS-CoV-2 Pathogenesis in COVID-19

por Undi, Ram Babu, Larabee, Jason L., Filiberti, Adrian, Ulahannan, Susanna, Aravindan, Sheeja, Stroberg, Edana, Barton, Lisa M., Duval, Eric J., Mukhopadhyay, Sanjay, Henthorn, James C., Akins, Darrin, Houchen, Courtney W., Huycke, Mark M., Ali, Naushad
Publicado 2022

First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma

por Hamilton, Erika P., Wang, Judy S., Oza, Amit M., Patel, Manish R., Ulahannan, Susanna V., Bauer, Todd, Karlix, Janet L., Zeron-Medina, Jorge, Fabbri, Giulia, Marco-Casanova, Paola, Moorthy, Ganesh, Hattersley, Maureen M., Littlewood, Gillian M., Mitchell, Patrick, Saeh, Jamal, Pouliot, Gayle P., Moore, Kathleen N.
Publicado 2023

Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors

por Lim, Emerson A., Bendell, Johanna C., Falchook, Gerald S., Bauer, Todd M., Drake, Charles G., Choe, Jennifer H., George, Daniel J., Karlix, Janet L., Ulahannan, Susanna, Sachsenmeier, Kris F., Russell, Deanna L., Moorthy, Ganesh, Sidders, Ben S., Pilling, Elizabeth A., Chen, Huifang, Hattersley, Maureen M., Das, Mayukh, Kumar, Rakesh, Pouliot, Gayle P., Patel, Manish R.
Publicado 2022

Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial

por Schram, Alison M., Colombo, Nicoletta, Arrowsmith, Edward, Narayan, Vivek, Yonemori, Kan, Scambia, Giovanni, Zelnak, Amelia, Bauer, Todd M., Jin, Ning, Ulahannan, Susanna V., Colleoni, Marco, Aftimos, Philippe, Donoghue, Mark T. A., Rosen, Ezra, Rudneva, Vasilisa A., Telli, Melinda L., Domchek, Susan M., Galsky, Matthew D., Hoyle, Margaret, Chappey, Colombe, Stewart, Ross, Blake-Haskins, John A., Yap, Timothy A.
Publicado 2022

The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial

por Luke, Jason J., Patel, Manish R., Blumenschein, George R., Hamilton, Erika, Chmielowski, Bartosz, Ulahannan, Susanna V., Connolly, Roisin M., Santa-Maria, Cesar A., Wang, Jie, Bahadur, Shakeela W., Weickhardt, Andrew, Asch, Adam S., Mallesara, Girish, Clingan, Philip, Dlugosz-Danecka, Monika, Tomaszewska-Kiecana, Monika, Pylypenko, Halyna, Hamad, Nada, Kindler, Hedy L., Sumrow, Bradley J., Kaminker, Patrick, Chen, Francine Z., Zhang, Xiaoyu, Shah, Kalpana, Smith, Douglas H., De Costa, Anushka, Li, Jonathan, Li, Hua, Sun, Jichao, Moore, Paul A.
Publicado 2023